{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:31:58Z","timestamp":1788838318400,"version":"build-2803163510"},"reference-count":44,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>As biologic therapy is increasingly being utilized in the treatment of paediatric psoriasis, we aim to perform a systematic review and network meta\u2010analysis to compare the efficacy and safety of available biologic treatments for moderate to severe paediatric plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Relevant randomized controlled trials (RCTs) were searched for in PubMed, Embase, Cochrane CENTRAL and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link>\n                      . We performed a fixed\u2010effects frequentist network meta\u2010analysis (NMA) with the surface under the cumulative ranking curve (SUCRA) calculated for and mean ranking calculated. The main outcomes of interest were a \u226575% improvement in PASI score (PASI75), \u226590% improvement in PASI score (PASI90), 100% improvement in PASI score (PASI100), CDLQI score of 0\/1 (CDLQI 0\/1) at weeks 12\u201316 and safety outcomes at 12\u201320\u2009weeks. Point probabilities of response were also calculated, presented as absolute risk differences per 1000 patients with their 95% CIs compared to placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven RCTs comprising 1016 psoriasis patients were included. Compared to placebo, all biologic therapies exhibited a significantly higher PASI90 and PASI75 response. Based on the SUCRA, Ixekizumab ranked highest in achieving the PASI100 (SUCRA: 0.9, Mean Rank: 1.8) response. Secukinumab high dose ranked the best for PASI90 (SUCRA: 0.8, Mean Rank: 3.0). For the CDLQI 0\/1 (SUCRA: 0.8, Mean Rank: 2.2) response and the PASI75 (SUCRA: 0.9, Mean Rank: 2.2) response, standard dose Ustekinumab exhibited superior performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>All biologic agents (not including non\u2010biologic comparators methotrexate and FAEs) were significantly superior to placebo, with no significant difference between individual biologic therapies, for the treatment of moderate\u2010to\u2010severe paediatric plaque psoriasis. Ixekizumab and Secukinumab demonstrated a trend towards a higher PASI90 response, while Ustekinumab showed a trend towards increased CDLQI and PASI75 responses. These findings highlight the need for better\u2010powered trials in this population to determine the optimal treatment modality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO Number<\/jats:title>\n                    <jats:p>CRD42023476983.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70084","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:33:35Z","timestamp":1760556815000},"page":"597-609","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Biologics for treatment of paediatric plaque psoriasis: A systematic review and network meta\u2010analysis"],"prefix":"10.1111","volume":"40","author":[{"given":"Abdullah Ali","family":"Aljalfan","sequence":"first","affiliation":[{"name":"Department of Dermatology King Fahad University Hospital  Al Khobar Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Talha","family":"Maniya","sequence":"additional","affiliation":[{"name":"Department of Medicine Ziauddin University  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilshad","family":"Sachedina","sequence":"additional","affiliation":[{"name":"Department of Dermatology Boston Medical Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serene Raaed","family":"Almuhaidib","sequence":"additional","affiliation":[{"name":"College of Medicine Imam Abdulrahman Bin Faisal University  Dammam Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmajeed Sulaiman","family":"Alharbi","sequence":"additional","affiliation":[{"name":"College of Medicine Imam Abdulrahman Bin Faisal University  Dammam Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmah","family":"Alamrie","sequence":"additional","affiliation":[{"name":"Dermatology Department Dammam Medical Complex  Dammam Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umna","family":"Aziz","sequence":"additional","affiliation":[{"name":"Department of Medicine Dow International Medical College  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2101-8249","authenticated-orcid":false,"given":"Anusha Abdul Muqeet","family":"Farid","sequence":"additional","affiliation":[{"name":"Department of Medicine Ziauddin University  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2013.11.003"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10280.x"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112427"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.049"},{"key":"e_1_2_13_6_1","volume-title":"Product Information: Cosentyx\u00ae subcutaneous injection, secukinumab subcutaneous injection","year":"2021"},{"key":"e_1_2_13_7_1","unstructured":"U.S. Food and Drug Administration.Etanercept. U.S. Food and Drug Administration. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103795s5582lbl.pdf. Accessed July 2023."},{"key":"e_1_2_13_8_1","unstructured":"European Medicines Agency.Enbrel: EPAR \u2013 Summary for the public. European Medicines Agency website. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/overview\/enbrel\u2010epar\u2010summary\u2010public_en.pdf. Accessed July 2023."},{"key":"e_1_2_13_9_1","unstructured":"U.S. Food and Drug Administration.Stelara. U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125261s150lbl.pdf. Accessed July 2023."},{"key":"e_1_2_13_10_1","unstructured":"European Medicines Agency.Stelara: EPAR \u2013 Product information. European Medicines Agency website. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ste\u2010lara. Accessed July 2023."},{"key":"e_1_2_13_11_1","unstructured":"U.S. Food and Drug Administration.Cosentyx. U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125504_S050_S051lbl.pdf. Accessed July 2023."},{"key":"e_1_2_13_12_1","unstructured":"European Medicines Agency.Cosentyx: EPAR \u2013 Medicine overview. European Medicines Agency website. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/overview\/cosentyx\u2010epar\u2010medicine\u2010overview_en.pdf. Accessed July 2023."},{"key":"e_1_2_13_13_1","unstructured":"U.S. Food and Drug Administration.Taltz. U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125521s014lbl.pdf. Accessed July 2023."},{"key":"e_1_2_13_14_1","unstructured":"European Medicines Agency.P\/0087\/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz) (EMEA\u2010001050\u2010PIP01\u201010\u2010M05). European Medicines Agency website. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/pip\u2010decision\/p\/0087\/2020\u2010ema\u2010decision\u201018\u2010march\u20102020\u2010acceptance\u2010modification\u2010agreed\u2010paediatric\u2010investigation\u2010plan_en.pdf. Accessed July 2023."},{"key":"e_1_2_13_15_1","unstructured":"European Medicines Agency.Humira: EPAR \u2013 Procedural steps taken and scientific information after authorisation. European Medicines Agency website. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/humira\u2010epar\u2010product\u2010information_en.pdf. Accessed July 2023."},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2021.10864"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2020.09.012"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14832"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19063"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17002"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0655"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14892"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19747"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-022-00507-0"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.08.066"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500403"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0060-8"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1278"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/eb-2013-101340"},{"key":"e_1_2_13_32_1","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021)","author":"Page MJ","year":"2021"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00544-6"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1890683"},{"issue":"2","key":"e_1_2_13_35_1","first-page":"123","article-title":"New biologics in psoriasis: an update on IL\u201023 and IL\u201017 inhibitors","volume":"99","author":"Dong J","year":"2017","journal-title":"Cutis"},{"issue":"5","key":"e_1_2_13_36_1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"5","author":"Sbidian E","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.6.17815"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1278198"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.017"},{"issue":"3","key":"e_1_2_13_40_1","first-page":"323","article-title":"Efficacy and safety of etanercept in children and adolescents aged > or\u2009=\u20098\u2009years with severe plaque psoriasis","volume":"20","author":"Landells I","year":"2010","journal-title":"Eur J Dermatol"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.060"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066886"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.002"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31189-3"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18029"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70084","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70084","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:37:45Z","timestamp":1776868665000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/jdv.70084"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70084","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"2024-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}